ArticlePLOS global public health2026
Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- "Fragmented care pathway in a layered TB care system": a grounded theory approach to understand care pathways and delays in TB care in Odisha.BMC health services research · 2026Article
- Comparison of active and passive case finding on diagnostic delay and treatment outcomes in older patients with pulmonary tuberculosis: a cohort study using real-world data.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tuberculosis (TB) care for people with TB in India are often fragmented, undermining timely diagnosis and treatment. Understanding patient journeys is critical to strengthening TB care delivery and advancing elimination goals. We conducted a cross-sectional study of 400 people with TB diagnosed between 2020-2022 in two Indian cities: Mumbai (n = 200) and Patna (n = 200). Using structured interviews, we assessed care-seeking behavior, delays to diagnosis and treatment, the number and type of healthcare encounters, and out-of-pocket costs. Participants predominantly initiated care in the private sector (Mumbai 91%; Patna 85%), often at pharmacies or private clinics. Care journeys were fragmented, with multiple provider visits before diagnosis. The median total delay from symptom onset to treatment initiation was 35 days (IQR 13-81) in Patna and 26 days (IQR 12-59) in Mumbai. Provider delays contributed a median of ~19 days in both cities. Participants made a median of 3 pre-diagnosis healthcare visits, and 23% had ≥ 6 encounters. The financial burden was substantial particularly in Mumbai, where consultation and diagnostic costs were higher than in Patna. Longer delays and more encounters were associated with male sex, unemployment, larger household size, and care-seeking hesitancy during the study period. Patient journeys in urban India during the COVID-19 pandemic were prolonged and costly, with delays driven primarily by systemic fragmentation rather than patient hesitancy. The reliance on an under-regulated private sector led to multiple pre-diagnosis encounters (23% requiring more than 6) and significant out-of-pocket costs. Because no individual characteristic consistently predicted delay, these findings suggest that structural reforms including standardized diagnostic pathways and enhanced public-private integration are essential to build health system resilience and accelerate TB elimination.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.